How did a biotech firm that just about ran out of cash thrice get acquired for over $3 billion? Will the M&A streak proceed? And why are drugmakers working with a telehealth firm known as Prescribery?
We focus on all that and extra on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Enterprise capitalist Bryan Roberts joins us to debate his agency’s funding in Kelonia Therapeutics, the CAR-T biotech that Eli Lilly simply stated it might purchase for $3.25 billion.
We additionally convey on our colleague Katie Palmer to speak by means of her story about pharma firms utilizing bargain-basement telehealth suppliers to drive drug prescriptions and gross sales.
To examine Lilly’s acquisition of Kelonia and the biotech’s preliminary funding pitch, go right here.; to learn extra about pharma firms’ new technique with telehealth, go right here; and for extra on Medicare delaying its weight problems drug protection pilot, go right here.
Make sure to enroll in “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.
